Categories: News

JPMorgan ETFs (Ireland) ICAV: Change of Index for various sub-funds

DUBLIN, Ireland, Jan. 15, 2021 (GLOBE NEWSWIRE) —

JPMorgan ETFs (Ireland) ICAV

Notice of Index Change

Please note that effective 29 January 2021 the following Index Tracking Sub-Funds will change Index in order to retain the current index exit maturity rules and the Sub-Fund Supplements will be updated accordingly. There will be no change to how the Sub-Funds are managed in practice.

JPMorgan ETFs (Ireland) ICAV – BetaBuilders US Treasury Bond UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders US Treasury Bond 1-3 yr UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders UK Gilt 1-5 yr UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders EUR Govt Bond UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders EUR Govt Bond 1-3 yr UCITS ETF

To view the full details, please paste the following URL into the address bar of your browser.

https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/supplemental/notice-to-shareholders/jpm-etfs-ireland-icav-index-changes-en.pdf

Enquiries:

JPMorgan
Annabel Dow
annabel.s.dow@jpmorgan.com
+44 207 7428379

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Staff

Recent Posts

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

New findings support the company's neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized…

2 hours ago

Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to…

2 hours ago

MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment

SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facilityUI Pharmaceuticals…

2 hours ago

RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air

LAS VEGAS, Jan. 10, 2025 /PRNewswire/ -- RingConn, a leading smart wearable brand, is proud…

2 hours ago

1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly Report and Announces Management Changes

VANCOUVER, BC / ACCESSWIRE / January 10, 2025 / 1933 Industries Inc. (the "Company" or…

2 hours ago